Avalo Therapeutics (AVTX) announced the appointment of Kevin Lind to its Board of Directors. He most recently served as President, CEO, and Board Member of Longboard Pharmaceuticals.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright
- Oppenheimer buyers of Avalo Therapeutics ahead of lutikizumab data
- 3 Best Stocks to Buy Now, 9/12/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 9/5/2025, According to Top Analysts
- Buy Rating for Avalo Therapeutics Driven by Promising AVTX-009 Development and Market Potential